





































Risk factors for antiretroviral therapy (ART) 
discontinuation in a large multinational trial
of early ART initiators
Loveleen Bansi-Matharua, Gabriela Rodriguez Loriab, Stephen R. Colec,
Henry Mugerwad, Isabel Vecinoe, Jens Lundgrenf, Piotr Pulikg,
Colette Smitha, Andrew N. Phillipsa, for the INSIGHT
START Study Group
Objective: We aimed to investigate potential causes of higher risk of treatment 
interruptions within the multicountry Strategic Timing of AntiRetroviral Treatment 
(START) trial in 2015.
Methods: We defined baseline as the date of starting antiretroviral therapy (ART) and a 
treatment interruption as discontinuing ART for at least 2 weeks. Participants were 
stratified by randomization arm and followed from baseline to earliest end date of the 
initial phase of START, death, date of consent withdrawn or date of first treatment 
interruption. Cox regression was used to calculate hazard ratios and 95% confidence 
intervals for factors that may predict treatment interruptions in each arm.
Results: Of the 3438 participants who started ART, 2286 were in the immediate arm 
and 1152 in the deferred arm. 12.9% of people in the immediate arm and 10.5% of 
people in the deferred arm experienced at least one treatment interruption by 3 years 
after starting ART. In adjusted analyses, age [hazard ratio for 35–50 years: 0.75 (95%
confidence interval: 0.59–0.97) and >50 years: 0.53 (0.33–0.80) vs. <35 years], 
education status [hazard ratio for postgraduate education vs. less than high-school 
education (0.23 (0.10–0.50))] and region [hazard ratio for United States vs. Europe/
Israel (3.16 (2.09–4.77))] were significantly associated with treatment interruptions in 
the immediate arm. In the deferred arm, age and education status were significantly 
associated with treatment interruptions.
Conclusion: Within START, we identified younger age and lower educational attain-
ment as potential causes of ART interruption. There is a need to strengthen adherence 
advice and wider social support in younger people and those of lower education status. 
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Introduction
In 2015, results published from the large-scale, multi-
country Strategic Timing of AntiRetroviral Treatment
(START) trial showed that, among people with a CD4þ
cell count above 500/ml, starting treatment straight away,
rather than delaying until the CD4þ cell count was lower
than 350 cells/ml or an AIDS disease had occurred,
reduced the risk of developing serious AIDS and non-
AIDS diseases [1].
People who start antiretroviral therapy (ART) early will
tend to be on treatment for a longer period than those
who defer treatment, and while current drugs are
substantially more tolerable now than they once were,
most are still not without side effects [2]. This, along with
other reasons such as travel, important distracting life
events, perceived and possibly real impact of treatment on
quality of life, may result in treatment interruptions. This
is despite the evidence from the earlier Strategies for
Management of Antiretroviral Therapy trial showing the
detrimental effects of treatment interruption [3].
It has been shown that certain groups are more likely to
interrupt treatment than others. Although studies are
differentiated by both definitions of interruption and
inclusion criteria, recent studies suggest men are at higher
risk of interruption than women [4–6], although some
earlier studies have shown a higher risk in women [7,8].
People who inject drugs and those of younger age have
also been shown to be at an increased risk of treatment
interruption [7–11], as have those with low educational
attainment [10].
Although risk factors associated with treatment inter-
ruptions have previously been studied, we place focus on
early ART initiators in a multinational trial. Using data
from the START trial, we aimed to gain insights into
what factors potentially cause a raised risk of treatment
interruption.
Methods
The START trial was designed and conducted by the
International Network for Strategic Initiatives in Global
HIV Trials. People were eligible for the study if they were
HIV positive, aged more than 18 years of age, had not yet
initiated ART and had two CD4þ cell counts of more
than 500 cells/ml at least 2 weeks apart within 60 days
before enrolment. People were randomized to either
immediate initiation of ART or deferred initiation until
CD4þ cell count dropped to 350 cells/ml or occurrence
of an AIDS defining disease or another condition that
dictated the use of antiretroviral therapy (e.g. pregnancy).
(For full details regarding the original study design, see the
study protocol, available at NEJM.org.)
For these analyses, we defined baseline as the date of
starting ART. A treatment interruption was defined as
stopping all antiretroviral treatment for at least 2 weeks,
regardless of the cause of interruption: that is both
clinician-directed and self-reported interruptions (>75%
of interruptions were self-reported) were included. Self-
reported interruptions were ascertained using informa-
tion from the ‘Adherence to ART’ questionnaires (1–203
and 1–203A) and amalgamated with the prescribed ART
information. Participants were followed from baseline
(the start of ART, the earliest of which was May 2009) to
whichever occurred first for the following: end date of the
initial phase of START (26 May 2015, based on an
interim review of the study data by the study’s
Independent Data and Safety Monitoring Board), death,
date of consent withdrawn, last known date of being alive
or the date of first treatment interruption.
Kaplan–Meier analyses, stratified by randomization arm,
were used to estimate the proportion of people who
experienced a treatment interruption. Univariable and
multivariable Cox proportional-hazards models, stratified
by randomization arm were used to calculate hazard ratios
and 95% confidence intervals for characteristics measured
at time of start of ART that may predict treatment
interruptions: age, sex/mode of acquisition, education
status, region, CD4þ and viral load. We also calculated
hazard ratios for specific antiretroviral drugs prescribed as
the initial regimen; the nucleoside reverse-transcriptase
inhibitor (NRTI) backbone was categorized as tenofo-
virþ lamivudine/emtricitabine (TDFþ 3TC/FTC),
abacavir (ABC) þ3TC/FTC, zidovudine (ZDV)þ 3TC
3TC or ‘other combination’ and the ‘third’ drug in the
regimen was categorized as efavirenz (EFV), other non-
nucleoside reverse-transcriptase inhibitor (NNRTI),
boosted atazanavir (ATV), boosted darunavir (DRV),
other boosted protease inhibitor (PI), any integrase
inhibitor or ‘other’.
Results
Of the 4684 HIV positive participants who were
randomized 3438 participants started ART for the first
time prior to May 2015 [median time from start of ART
to study end/withdrawal/death¼ 31.0 (interquartile
range: 21.8–43.1) months]; 2286 of these participants
were in the immediate arm and 1152 in the deferred arm.
The median time from randomization to starting ART in
the immediate arm was 0.2 (0.1–0.5) months and in the
deferred arm was 18.7 (10.3–29.0) months. In total, 380
(11.1%) participants experienced at least one treatment
interruption and of these, 40 participants (10.5%) did not
restart treatment before the study end date. By 3 years
after starting ART, 12.9% (Kaplan–Meier estimate) of
people in the immediate arm and 10.5% of people in the
deferred arm experienced at least one treatment
interruption.
The median duration of interruption among those who
restarted ARTwas 43 (22–93) days and 59 (30–164) days
in the immediate and deferred arms, respectively. Baseline
characteristics stratified by randomization arm are shown
in Table 1.
In the immediate arm, lower age, IDU/heterosexual
female risk groups, lower education status, higher CD4þ
cell count, lower viral load and receiving ZDVand 3TC as
the NRTI backbone were significantly associated with
treatment interruptions in univariable Cox proportional
hazards model (Table 2, immediate arm, univariable
analyses). Region was also significantly associated with
treatment interruptions; those from Africa, Latin
America, United States and Asia were at an increased
risk of treatment interruption compared with those from
Europe and Israel. In multivariable analyses, only age,
education status, region and NRTI backbone remained
significantly associated with treatment interruptions
(Table 2, immediate arm, multivariable results). Similar
univariable results were seen in the deferred arm, albeit
with stronger associations between the factor of interest
and the risk of treatment interruption (Table 2, deferred
Table 1. Baseline characteristics stratified by treatment interruption and randomization arm.
Treatment interruption
Immediate, n¼2286 Deferred, n¼1152
No Yes No Yes
1993 (87.2) 293 (12.8) 1065 (92.4) 87 (7.6)
Age
<35 years 869 (84.7) 157 (15.3) 427 (89.5) 50 (10.5)
35–50 years 874 (88.6) 112 (11.4) 464 (94.3) 28 (5.7)
>50 years 250 (91.2) 24 (8.8) 174 (95.1) 9 (4.9)
Sex/mode of acquisition
IDU 28 (75.7) 9 (24.3) 12 (80.0) 3 (20.0)
MSM 1138 (88.9) 142 (11.1) 733 (94.5) 43 (5.5)
Heterosexual female 462 (83.2) 93 (16.8) 173 (86.9) 26 (13.1)
Heterosexual male 265 (88.0) 36 (12.0) 101 (91.0) 10 (9.0)
Other 100 (88.5) 13 (11.5) 46 (90.2) 5 (9.8)
Education
Less than high school 544 (80.1) 135 (19.9) 203 (86.0) 33 (14.0)
High school graduate 447 (88.6) 69 (13.4) 216 (91.9) 19 (8.1)
Completed vocational training 189 (90.4) 20 (9.6) 121 (93.8) 8 (6.2)
Some college/university 344 (83.4) 41 (10.7) 197 (92.5) 16 (7.5)
Bachelor’s degree 354 (94.4) 21 (5.6) 250 (97.3) 7 (2.7)
Any postgraduate education 115 (94.3) 7 (5.7) 78 (95.1) 4 (4.9)
Region
Africa 430 (87.8) 60 (12.2) 117 (86.0) 19 (14.0)
Latin America 483 (82.8) 98 (17.2) 253 (93.7) 17 (6.3)
Europe and Israel 701 (93.3) 50 (6.7) 465 (94.5) 27 (5.5)
United States 196 (80.3) 48 (19.7) 134 (87.6) 19 (12.4)
Australia 49 (87.5) 7 (12.5) 34 (94.4) 2 (5.6)
Asia 144 (82.8) 30 (17.2) 62 (95.4) 3 (4.6)
NRTI backbone
TDFþ3TC/FTC 1797 (88.7) 228 (11.3) 958 (93.0) 72 (7.0)
ABCþ3TC/FTC 61 (85.9) 10 (14.1) 65 (92.9) 5 (7.1)
ZDVþ3TC 133 (70.7) 55 (29.3) 37 (80.4) 9 (19.6)
Other combination 2 (100.0) 0 (0.0) 5 (83.3) 1 (16.7)
Third drug
EFV 1445 (87.1) 215 (12.9) 539 (92.9) 41 (7.1)
Other NNRTI 92 (94.9) 5 (5.1) 144 (92.3) 12 (7.7)
ATV 190 (83.0) 39 (17.0) 85 (87.6) 12 (12.4)
DRV 147 (90.2) 16 (9.8) 116 (92.1) 10 (7.9)
Other PI 25 (80.7) 6 (19.3) 24 (85.7) 4 (14.3)
INSTI 91 (89.2) 11 (10.8) 153 (95.0) 8 (5.0)
Other 3 (75.0) 1 (25.0) 5 (100.0) 0 (0.0)
CD4þ at start of ART
cells/ml 647 (579–757) 666 (596–788) 405 (319–563) 463 (329–593)
Viral load at start of ART
copies/ml 14 328 (3413–46 000) 9453 (2609–35 880) 41 700 (12 700–120 000) 35 100 (12 761–97 957)
3TC, lamivudine; ABC, abacavir; ATV, boosted atazanavir; DRV, boosted darunavir; EFV, efavirenz; FTC, emtricitabine; INSTI, integrase strand
transfer inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor;
TDF, tenofovir; ZDV, zidovudine.
arm, univariable results). In multivariable analyses, only
age and education status were significantly associated with
treatment interruptions (Table 2, deferred arm, multivar-
iable results).
Discussion
Using data from a diverse multinational cohort of
participants in the START trial, we found that 12.9% of
people who started ART in the immediate arm and
10.5% of those who started ART in the deferred arm
had at least one treatment interruption after 3 years of
starting ART. Treatment interruptions took place on
average 5 months after starting ART and generally
lasted from 3 to 15 weeks. We found that after adjusting
for potential confounders, participants who started
ART were more likely to experience treatment
interruptions if they were of younger age and had
lower education status. Region and the NRTI
backbone used was significantly associated with
treatment interruptions in the immediate arm but
not in the deferred arm.
Table 2. Univariable and multivariable hazard ratios for treatment interruptions stratified by randomization arm.
Immediate arm Deferred arm
Univariable Multivariable Univariable Multivariable
Hazard ratios
(95% CI) P value
Hazard ratios
(95% CI) P value
Hazard ratios
(95% CI) P value
Hazard ratios
(95% CI) P value
Agea
<35 years 1 1 0.01 1 0.01 1 0.01
35–50 years 0.74 (0.58–0.95) 0.01 0.75 (0.59–0.97) 0.53 (0.33–0.84) 0.54 (0.34–0.88)
>50 years 0.58 (0.38–0.90) 0.52 (0.33–0.80) 0.49 (0.24–0.99) 0.43 (0.21–0.90)
Sex/mode of acquisitiona
IDU 2.34 (1.19–4.59) 0.001 1.63 (0.80–3.30) 0.46 3.40 (1.06–10.95) 0.001 3.30 (0.95–11.50) 0.17
MSM 1 1 1 1
Heterosexual female 1.71 (1.31–2.22) 1.24 (0.88–1.74) 2.86 (1.75–4.66) 1.85 (0.98–3.49)
Heterosexual male 1.18 (0.82–1.70) 0.98 (0.66–1.47) 1.78 (0.90–3.55) 1.64 (0.78–3.44)
Other 1.09 (0.62–1.92) 0.97 (0.54–1.76) 1.87 (0.74–4.73) 1.57 (0.61–4.09)
Educationa
Less than high school 1 <0.0001 1 <0.0001 1 0.0001 1 0.03
High school graduate 0.63 (0.47–0.84) 0.48 (0.35–0.66) 0.52 (0.30–0.92) 0.58 (0.31–1.07)
Completed vocational
training
0.42 (0.27–0.68) 0.45 (0.27–0.76) 0.35 (0.16–0.77) 0.51 (0.22–1.16)
Some college/university 0.49 (0.34–0.69) 0.35 (0.24–0.52) 0.49 (0.27–0.88) 0.50 (0.25–0.98)
Bachelor’s degree 0.25 (0.16–0.39) 0.22 (0.14–0.36) 0.16 (0.07–0.37) 0.22 (0.09–0.53)
Any postgraduate
education
0.26 (0.12–0.55) 0.23 (0.10–0.50) 0.28 (0.10–0.78) 0.42 (0.14–1.28)
Regiona
Africa 2.16 (1.48–3.15) <0.0001 1.04 (0.67–1.63) <0.0001 3.35 (1.86–6.05) 0.001 1.26 (0.60–2.66) 0.39
Latin America 2.97 (2.11–4.18) 2.70 (1.90–3.84) 1.38 (0.75–2.53) 1.23 (0.66–2.31)
Europe and Israel 1 1 1 1
United States 3.14 (2.11–4.67) 3.16 (2.09–4.77) 2.29 (1.27–4.12) 1.99 (1.06–3.73)
Australia 1.86 (0.84–4.10) 2.03 (0.91–4.52) 0.98 (0.23–4.12) 1.15 (0.27–4.86)
Asia 2.97 (1.89–4.68) 2.23 (1.37–3.65) 0.90 (0.27–2.97) 0.81 (0.24–2.75)
CD4þ at start of ARTa
Per 50 cells higher 1.04 (1.01–1.07) 0.01 1.02 (0.99–1.05) 0.21 1.04 (0.99–1.09) 0.13 1.02 (0.97–1.08) 0.35
Viral load at start of ARTa
Per 1 log higher 0.83 (0.74–0.94) 0.004 0.95 (0.82–1.09) 0.45 0.87 (0.68–1.11) 0.25 1.08 (0.83–1.40) 0.57
NRTI backboneb
TDFþ3TC/FTC 1.24 (0.66–2.33) <0.0001 1.54 (0.79–3.01) <0.0001 0.97 (0.39–2.39) 0.01 1.01 (0.39–2.64) 0.35
ABCþ3TC/FTC 1 1 1 1
ZDVþ3TC 2.77 (2.06–3.71) 2.14 (1.53–3.01) 2.78 (1.39–5.56) 1.90 (0.80–4.51)
Third drugb
EFV 1 0.12 1 0.30 1 0.46 1 0.36
Other NNRTI 0.44 (0.18–1.06) 0.52 (0.21–1.29) 1.19 (0.62–2.26) 1.39 (0.66–2.93)
ATV 1.28 (0.91–1.80) 1.37 (0.95–1.97) 1.66 (0.87–3.17) 2.10 (1.04–4.27)
DRV 0.71 (0.43–1.18) 1.06 (0.61–1.83) 0.99 (0.49–1.97) 1.29 (0.58–2.88)
Other PI 1.40 (0.62–3.15) 1.35 (0.60–3.06) 1.90 (0.68–5.29) 0.73 (0.22–2.44)
INSTI 0.84 (0.46–1.55) 1.19 (0.63–2.24) 0.79 (0.37–1.69) 1.01 (0.43–2.36)
3TC, lamivudine; ABC, abacavir; ATV, boosted atazanavir; CI, confidence interval; DRV, boosted darunavir; EFV, efavirenz; FTC, emtricitabine;
INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor;
PI, protease inhibitor; TDF, tenofovir; ZDV, zidovudine.
aMultivariable model mutually adjusted for age, sex/mode of acquisition, education, region, CD4þ and viral load.
bMultivariable model adjusted for age, sex/mode of acquisition, education, region, CD4þ and viral load.
Our finding of a higher risk of treatment interruption
(regardless of randomization arm) among those of
younger age is consistent with earlier studies [7–11]. It
is possible that younger people are less stable both in terms
of living conditions (less likely to be in permanent
housing) and socially, and this may impact on taking
treatment regularly.
Level of education was also independently associated with
treatment interruptions in both the immediate and
deferred arms. The association between education and
treatment interruptions/low adherence has been shown
in other studies [10,12,13]. Education attainment is also
linked to a greater ability to deal with life events due to
enhanced psychosocial skills [14]. Hence, those
experiencing difficult life events who have higher
education attainment may be less likely to interrupt
therapy than those with lower education attainment, and
they may also have greater support available when such
events occur. Higher education is generally seen, at least
partially, as a proxy for socioeconomic status and is likely
to be linked to increased health literacy and in turn better
adherence to medication. We note that socioeconomic
status is a potentially important unmeasured confounder
in our study which prohibited exploration of the
independent potentially causal roles of education and
socioeconomic status.
Region was significantly associated with treatment
interruption. People from the United States were over
three times more likely to experience treatment
interruptions than people from Europe and Israel, while
those from Latin America and Asia had over double the
risk of experiencing a treatment interruption. Regional
differences could partially reflect differences in healthcare
systems leading to different selection factors affecting who
is enrolled. For example, within the United States, people
from lower socioeconomic status may have been more
likely to enrol in the trial to gain access to free medication.
General adherence to ART may also explain the finding
between region and interruption. In a systematic review
of young adults, Kim et al. [15] found that people from
North America had the lowest average ART adherence,
though this was followed by those from Europe and South
America, with higher levels seen in Africa and Asia. A
meta-analysis which included HIV-infected adults in
North America and sub-Saharan Africa also showed low
levels of adherence among people from North-America
compared with sub-Saharan Africa [16]. This may be due
to the epidemic being more generalized in sub-Saharan
Africa and hence ART provision and adherence
counselling being more widespread. In the United States,
the epidemic is more focussed among certain communi-
ties, in which health care may not be fully utilized, despite
the overall richer resource setting. However, it is likely
that the epidemic is similarly focussed in certain
communities in Europe and hence this explanation is
unlikely to fully explain the association seen. Another
possible explanation is that health systems within Europe
place a greater emphasis on the importance of adherence
and risks of interruption by delivering specific counsel-
ling to people which may not be available for a range of
reasons, including financial constraints on healthcare
budgets, outside of Europe. Other factors such as
physician experience [17], relationship with healthcare
provider [18] and mental health [19] have also been
shown to be associated with the risk of treatment
interruptions, whereas outside the setting of a random-
ized controlled trial, factors such as different healthcare
policies and treatment options may also contribute to
this risk.
Further, we cannot rule out the possibility of other
unmeasured confounding; participants from countries in
which a higher rate of treatment interruption was seen
may have personal attributes (e.g. attitudes to health care
and provision) which contribute to a higher risk of
interruption but were not captured within the study.
People receiving ZDVþ 3TC in the immediate arm had
a significantly increased risk of interruption compared
with those receiving other NRTI backbone regimens. A
considerable proportion of people in Latin America
(20%) and Africa (8%) were receiving ZDVþ 3TC as
their first regimen and one likely reason for discontinua-
tion among these people is the poorer toxicity profile
associated with ZDV compared with newer drugs [20].
Most of these people had enrolled onto the trial prior to
the end of 2013 and the proportion being prescribed this
backbone combination has since declined.
Although people interrupt treatment for a range of
reasons, it is of concern that within our multinational
study in which we were able to separately analyse risk
factors for treatment interruptions among early initiators,
selected subgroups are still more likely to interrupt
treatment. Further work to confirm these findings is
needed. Interrupting therapy is associated with long-term
poorer outcomes [3]. Improved approaches to support
young people and those with lower educational attain-
ment to sustain their taking of antiretrovirals are required.
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